全文获取类型
收费全文 | 506篇 |
免费 | 62篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 35篇 |
妇产科学 | 2篇 |
基础医学 | 71篇 |
口腔科学 | 5篇 |
临床医学 | 53篇 |
内科学 | 155篇 |
皮肤病学 | 10篇 |
神经病学 | 13篇 |
特种医学 | 5篇 |
外科学 | 33篇 |
综合类 | 11篇 |
预防医学 | 74篇 |
眼科学 | 1篇 |
药学 | 26篇 |
肿瘤学 | 72篇 |
出版年
2021年 | 5篇 |
2019年 | 5篇 |
2016年 | 5篇 |
2014年 | 6篇 |
2013年 | 10篇 |
2012年 | 16篇 |
2011年 | 10篇 |
2008年 | 10篇 |
2007年 | 17篇 |
2006年 | 13篇 |
2005年 | 23篇 |
2004年 | 11篇 |
2003年 | 13篇 |
2002年 | 12篇 |
2001年 | 11篇 |
2000年 | 18篇 |
1999年 | 8篇 |
1998年 | 8篇 |
1996年 | 5篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1993年 | 7篇 |
1992年 | 15篇 |
1991年 | 21篇 |
1990年 | 11篇 |
1989年 | 22篇 |
1988年 | 13篇 |
1987年 | 20篇 |
1986年 | 14篇 |
1985年 | 9篇 |
1984年 | 10篇 |
1983年 | 19篇 |
1982年 | 5篇 |
1979年 | 16篇 |
1978年 | 11篇 |
1977年 | 4篇 |
1976年 | 9篇 |
1975年 | 10篇 |
1974年 | 14篇 |
1973年 | 13篇 |
1972年 | 9篇 |
1971年 | 5篇 |
1970年 | 8篇 |
1969年 | 4篇 |
1968年 | 12篇 |
1967年 | 4篇 |
1966年 | 8篇 |
1963年 | 5篇 |
1962年 | 6篇 |
1958年 | 4篇 |
排序方式: 共有568条查询结果,搜索用时 31 毫秒
1.
W W Storms C W Bierman H Chai R J Dockhorn P Eggleston E F Ellis C Feldman J N Fink M P Hemstreet W T Kniker 《The Journal of asthma》1991,28(5):369-379
This multiclinic study was performed to evaluate the safety and efficacy of metaproterenol sulfate (Alupent) metered dose inhaler in children with asthma ages 5 to 12 years. A total of 268 children completed this study according to the protocol, having received either metaproterenol or placebo for 30 consecutive days. Full spirometric testing was done pre- and postdose on Days 1 and 30 for a total duration of 6 hours on each day. The results showed that metaproterenol was consistently superior to placebo in all pulmonary function parameters measured on Days 1 and 30. This difference was statistically significant for peak values and areas under the curves for both FEV1 and FEF25-75%. There were no significant side effects noted. We conclude that metaproterenol metered dose inhaler is safe and effective in the treatment of asthma in children ages 5 to 12 years. 相似文献
2.
J W Gaffney F Z Bierman C M Donnelly M Sutton S Piomelli W M Gersony 《The American journal of cardiology》1988,62(1):121-125
The effect of transfusion/chelation therapy on the cardiovascular adaptations to chronic anemia in pediatric and young adult patients with homozygous sickle cell disease is uncertain. This study compares left ventricular (LV) function indexes and thoracoabdominal aortic systolic and diastolic blood flow in nontransfused and transfused patients with homozygous sickle cell disease. The study population consisted of 29 nontransfused patients with homozygous sickle cell disease, ages 0.4 to 20.9 years (group 1) and 11 chronically transfused/chelated patients, ages 4.0 to 21.8 years (group 2). The mean total hemoglobin concentration in group 2 was 28% greater than that in group 1. The mean duration of transfusion/chelation therapy in group 2 was 3.7 years. The percent of predicted LV end-diastolic and end-systolic dimensions were significantly greater than the respective controls in both groups. There was no significant difference in percent of predicted LV end-diastolic dimension (group 1, 120 +/- 12%; group 2, 120 +/- 12%) or percent of predicted LV end-systolic dimension (group 1, 120 +/- 12%; group 2, 117 +/- 8) between the groups. The percent of LV shortening fraction was similar in study groups and control subjects. Aortic systolic blood flow (cc/min/m2) for group 1 (2,426 +/- 841) and 2 (2,374 +/- 1.004) were significantly greater than corresponding control values (1,683 +/- 442, 1,736 +/- 430, respectively). Aortic diastolic blood flow was significantly greater than corresponding control values for both group 1 (699 +/- 313 vs 488 +/- 212) and group 2 (1,080 +/- 607 vs 588 +/- 219).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
3.
W P Vaughan J D Dennison E C Reed L Klassen T R McGuire W G Sanger P P Kumar P I Warkentin B G Gordon P J Bierman 《Bone marrow transplantation》1991,8(6):489-495
Twenty-four patients between the ages of 8 and 48 years (median 27.5) with high-risk for relapse hematologic malignancy received a marrow transplant from an HLA and MLC compatible sibling donor after chemotherapy with busulfan, 4 mg/kg/day for 4 days by mouth, cyclophosphamide 60 mg/kg/day i.v. for 2 days, and etoposide 60 mg/kg i.v. over 4 h on the first day of cyclophosphamide treatment (BU/CY/VP). Toxicity consisted of mucositis, skin rash, and nausea and vomiting in all patients, transient fever thought to be due to etoposide administration in 16/24 (67%) patients, and clinical veno-occlusive disease (VOD) of the liver in 4/24 (17%). There were nine deaths from causes other than recurrent disease in the first 100 days after transplant and two deaths after day 100, a total transplant mortality of 11/24 (46%). Three patients relapsed, but 10/24 (40%) remain alive and disease free 26-182 weeks (median 60 weeks) from transplant. These results compare favorably with results in a group of 12 similar risk patients treated with total body irradiation (TBI) containing regimens during an overlapping time period. Six of the TBI patients have had persistent or recurrent disease and only two (17%) are currently alive and disease free. The probability of disease persistence or relapse is 67% in the TBI group and 20% in the BU/CY/VP group (p less than 0.02). 相似文献
4.
Chien Yie W. Chien Te-yen Bagdon Robert E. Huang Yih C. Bierman Robert H. 《Pharmaceutical research》1989,6(12):1000-1010
Several transdermal contraceptive device (TCD) formulations were developed to provide a dual-controlled transdermal delivery of levonorgestrel (LN), a potent progestin, and 17-estradiol (E2), a natural estrogen. Using a sensitive HPLC method, the in vitro release and skin permeation profiles of LN and E2 from various TCD formulations were simultaneously characterized in the hydrodynamically well-calibrated Valia–Chien skin permeation cells and both were found to follow zero-order kinetics. The rates of drug release and skin permeation were observed to vary significantly depending upon some formulation parameters. Six-month stability studies were performed on seven formulations at room and elevated temperatures (37 and 45°C), and two (Formulations 4 and 5) were found to be acceptable, based on drug recovery, release rate, and skin permeation rate data. Judging from the 6-month accelerated stability studies, it is projected these two formulations will have shelf-life of at least 2 years. As a result of development of an efficient manufacturing process, Formulation 4 was selected for further evaluation. One-week primary skin irritation evaluation in 6 rabbits indicated that Formulation 4 is nonirritating, and it was thus selected for Phase I clinical bioavailability/dose proportionality studies in 12 healthy female volunteers of child-bearing age. Results of pharmacokinetic and pharmacodynamic analyses demonstrated that it is capable of achieving and maintaining a steady-state serum level of LN throughout the 3-week treatment period by weekly applications of one or two TCD patches (10 or 20 cm2). A dose proportionality was obtained in the serum drug levels, daily dose delivered, and contraception efficacy. An excellent correlation was obtained for the rates of transdermal delivery determined by the in vitro studies using human cadaver skin, the in vivo studies in rabbits, and the clinical studies in living subjects. 相似文献
5.
Edward?J?HolloxEmail author Jane?Davies Uta?Griesenbach Juliana?Burgess Eric?WFW?Alton John?AL?Armour 《Journal of negative results in biomedicine》2005,4(1):9
Human beta-defensin 2 (DEFB4, also known as DEFB2 or hBD-2) is a salt-sensitive antimicrobial protein that is expressed in
lung epithelia. Previous work has shown that it is encoded in a cluster of beta-defensin genes at 8p23.1, which varies in
copy number between 2 and 12 in different individuals. We determined the copy number of this locus in 355 patients with cystic
fibrosis (CF), and tested for correlation between beta-defensin cluster genomic copy number and lung disease associated with
CF. No significant association was found. 相似文献
6.
7.
8.
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. 总被引:6,自引:0,他引:6
Christine P Hans Dennis D Weisenburger Timothy C Greiner Wing C Chan Patricia Aoun Gregory T Cochran Zenggang Pan Lynette M Smith James C Lynch Robert Gregory Bociek Philip J Bierman Julie M Vose James O Armitage 《Modern pathology》2005,18(10):1377-1384
We sought to determine whether identification of poor-risk subgroups of diffuse large B-cell lymphoma (DLBCL) using immunohistochemical stains would have practical utility with regard to prognosis and therapeutic decisions. Tissue microarray blocks were created using replicate samples of formalin-fixed, paraffin-embedded tissue from 200 cases of de novo DLBCL. The sections were stained with antibodies to proteins that are expressed by activated or proliferating B cells including MUM1, FOXP1, bcl-2, survivin, protein kinase C-beta (PKC-beta), cyclin D2, cyclin D3, and Ki-67. In univariate analysis, tumor expression of cyclin D2 (P = 0.025) or PKC-beta (P = 0.015) was associated with a worse overall survival, whereas none of the other markers was predictive of overall survival. Patients with DLBCL that expressed either cyclin D2 or PKC-beta had a 5-year overall survival of only 30% as compared to 52% for those who were negative for both markers (P = 0.0019). In multivariate analysis, the expression of cyclin D2 or PKC-beta was an independent predictor of poor overall survival (P = 0.035). Cyclin D2 and PKC-beta expression will be useful in designing a 'biological prognostic index' for patients with DLBCL. 相似文献
9.
C Arbesman I L Bernstein C W Bierman J S Bocles R Katz P L Lieberman K Mattucci E O Meltzer E Middleton J Noyes D S Pearlman H L Pence R G Slavin S L Spector 《The Journal of allergy and clinical immunology》1983,71(6):597-603
Fluocortin butyl (FCB) is a newly synthesized corticosteroid with a high ratio of topical to systemic activity. FCB was studied in a multi-center, double-blind, placebo-controlled trial of therapy of perennial rhinitis. The study was conducted between January and May 1981. Patients evaluated suffered from either chronic allergic or chronic nonallergic rhinitis or both. A total of 306 patients from 16 investigative centers were evaluated by comparing FCB to placebo. Three separate dosage regimens were employed. Patients received a total daily dose of 2, 4, or 8 mg. FCB was found to be an effective therapeutic agent. It reduced symptoms of nasal congestion, rhinorrhea, postnasal drainage, and sneezing. It also markedly reduced the use of concomitant medications (chlorpheniramine maleate and/or pseudoephedrine). Relief of symptoms was noted as early as the first week of therapy, and the degree of improvement increased progressively during the study. There was little difference between the relief produced by the 4 mg and 8 mg regimens. Both of these were superior to the 2 mg regimen. The drug was well tolerated; no significant side effects were noted. 相似文献
10.
R. Michael Sly John A. Anderson C. Warren Bierman Paul Chervinsky Frederick C. Cogen James G. Easton Israel Glazer James P. Kemp Allan Knight Richard A. Krumholz Richard A. Nicklas Burton M. Rudolph Diane E. Schuller Allen T. Segal R. Michael Sly Stanley J. Szefler Michael J. Welch Ned J. Whitcomb Minoru Yamate 《The Journal of allergy and clinical immunology》1985,75(4):443-449